We thank Dr. Aycicek and colleagues [1] for their careful reading of our recently published work [2] in which we assessed factors influencing the increase in cardiac Troponin I (cTnI) and its prognostic value in hospitalized older patients.
Dear editor,
We thank Dr. Aycicek and colleagues [1] for their careful reading of our recently published work [2] in which we assessed factors influencing the increase in cardiac Troponin I (cTnI) and its prognostic value in hospitalized older patients.
In our study, we found that cardiovascular diseases (CVD) were statistically more frequent in patients positive on cTnI on admission. This positivity resulted as a mortality risk factor at 6 months after hospital stay. As outlined by the authors, we did not show if CVD were more common in patients who died in comparison with those who survived during the 6-month follow-up. Here we report the results on the prevalence of CVD in these groups of patients, who did not show any significant difference regarding congestive heart failure (23.5 vs. 23.1), coronary heart disease (41.2 vs. 31.1), myocardial infarction (23.5 vs. 14.3), arrhythmia (33.8 vs. 33.6 deceased vs survived patients in all comparisons).
Concerning having considered CVD in the regression analyses, we confirm that such comorbidities were taken into account by including in our models the variable "Heart diseases", defined as the presence of one among the following: congestive heart failure, coronary heart disease, myocardial infarction, arrhythmias or left ventricular hypertrophy.
With regard to the time elapsed between the initiation of the symptoms and admission to Emergency Department, this data was not collected and we recognize this as a limit of our study.
In conclusion, we thank Dr. Aycicek and colleagues for their accurate comments. We agree with them that further research is needed in the light of these suggestions to assess the real prognostic value of cTnI in older patients.
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